A two-drug combination for treating advanced kidney cancer has shown sustained and durable clinical benefit in more than five ...

A global study reveals that cutting-edge cancer immunotherapies, while lifesaving, carry a hidden risk: they may trigger ...

CAMBRIDGE, MA / ACCESS Newswire / July 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its ...

They evaluated pembrolizumab in patients with resectable stage II-IV (M0) cSCC. Patients received 200 mg pembrolizumab every 3 weeks for 4 cycles, followed by 18F-labeled fluorodeoxyglucose-positron ...

Facing patent expiration for its blockbuster Keytruda, Merck aims to streamline operations with significant job cuts and ...

NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announces that it will implement the Company’s previously disclosed plans to change the ratio of its American Depository Shares (“ADSs”) to its ...

Results from 2 studies suggest that adding ICIs to treatment can improve outcomes for patients with resectable HNSCC.

“I didn’t have any of the typical symptoms like blood in my poo, so the diagnosis came as a massive shock,” said Zara. Zara ...

We recently compiled a list of 11 Best Future Stocks to Buy Now. CG Oncology, Inc. stands sixth on our list. CG Oncology, Inc ...